AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05074524 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
Study NCT06517498 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention will be conducted
Study NCT05377112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB8802v1
Description: SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH. The strain converts oxalate to formate and CO2, two naturally occurring GI metabolites.~SYNB8802 was developed by engineering a pathway for oxalate degradation in a probiotic strain of Escherichia coli Nissle 1917 (EcN). It is intended to act within the GI tract to reduce the oxalate levels in patients with EH by converting oxalate to formate and CO2, two naturally occurring GI metabolites.
Study NCT05377112 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo powder will be aliquoted into high density polyethylene (HDPE) bottles and diluted in the same formulation buffer as SYNB8802v1 lyophilized powder. The placebo consists of corn starch and dyes to color match the placebo to the SYNB8802v1 powder for oral suspension
Study NCT06101147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: These patients will receive Vitamin D3 1000 I.U daily and the Metformin as prescribed by the physician for 8 weeks.
Study NCT06101147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: These patients will receive placebo and the Metformin as prescribed by the physician for the same periods of study group
Study NCT06004271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Exercise protocol:~Progressive Resistance Exercise Training Bridge exercise sit-up exercise functional walking exercise Stretching
Study NCT06004271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Exercise protocol:~Progressive Resistance Exercise Training Bridge exercise sit-up exercise functional walking exercise Stretching
Study NCT06004271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Description: Exercise protocol:~Progressive Resistance Exercise Training Bridge exercise sit-up exercise functional walking exercise Stretching
Study NCT06004271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and taping
Description: When applying kinesiology taping to the gluteus medius, first of all, for its anterior fiber, the tape portion will be attached lateral to the Spina iliaca anterior superior by giving a slight slope downwards from the crista iliaca with 50-75% tension. For the posterior fiber; Starting from the trochanter major, 50-75% tension will be applied along the muscle fiber.
Study NCT06004271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In the placebo tape application, the kinesiological tappings will be adhered horizontally without tension along the long line of the Tensor facie late muscle. The application to the ankle will be attached horizontally, without tension, slightly above the lateral malleolus.
Study NCT05048043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted Behavior Intervention
Description: The CABI includes a serious game called ATHEMOS that is designed to help students rehearse skills that ameliorate impairments associated with ADHD, including organization, scheduling, and note taking strategies. Once students have some experience with the game, a teacher consultee will help students actively transfer skills learned in the game to real-world classroom demands.
Study NCT05048043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Challenging Horizons Program
Description: The Challenging Horizons Program is an established psychosocial intervention package for young adolescents with ADHD, focusing on academic and behavioral impairments.
Study NCT04487808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pecan
Description: Unsalted raw pecans incorporated in snack and meal recipes as part of a dietary pattern
Study NCT04487808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Average American Diet devoid of nuts
Description: Diet mimicking usual American intake
Study NCT04617678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation Program
Description: We will assess whether prehabilitation intervention helps mitigate adverse symptoms (e.g., anxiety, depression, suicidality, distress, nutritional status, dysphagia, sarcopenia, and well-being) on a sample of head and neck cancer patients. Subjects will attend a Prepare for Surgery Heal Faster session and meet with a physical therapist, registered dietician, speech language pathologist, and masters of social work at pre-treatment, 6-8 weeks post-treatment, and 5-6 months post-treatment completion.
Study NCT06543303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTV100 Low dose
Description: 1% Cevimeline Ophthalmic Solution
Study NCT06543303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTV100 Mid dose
Description: 2% Cevimeline Ophthalmic Solution
Study NCT05888298 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Greater occipital nerve radiofrequency
Description: Greater nerve block and radiofrequency will be performed at the C2 vertebra level or occipital protuberance
Study NCT05888298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater occipital nerve radiofrequency
Description: Greater nerve block and radiofrequency will be performed at the C2 vertebra level or occipital protuberance
Study NCT04868773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral cabozantinib
Study NCT04868773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Oral TAS-102 (trifluridine and tipiracil)
Study NCT06543303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTV100 High dose
Description: 4% Cevimeline Ophthalmic Solution
Study NCT06543303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06560502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care-DFU
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
Study NCT06560502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmnioCore - DFU
Description: Participants will receive weekly applications of AmnioCore and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
Study NCT04407702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hygiene Instructions
Description: Two weeks prior to the onset of the study, the volunteers will undergo a wash-out period, in which they will only use oral hygiene products donated by the researchers. These products will be used through to the end of the study. The oral hygiene kit will contain a soft-bristle toothbrush (Professional Lab Series, Colgate Palmolive), fluoride toothpaste with no desensitizing agent (Elmex) and dental floss (Colgate). The participants will be extensively trained with regards to all procedures involved in the experiment.
Study NCT04407702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sealant application
Description: The teeth to be sealed will be isolated and 35% phosphoric acid will be applied for 20 seconds, followed by rinsing and drying the dental surfaces. A thin layer of PermaSeal will be applied to the tooth surface for 5 seconds and photopolymerized for 20 seconds. The occlusion will then be evaluated.
Study NCT04407702 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-level Laser
Description: Irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation. The power will be set to 100 mW; energy density will be 35 J/cm2 (considering a spot size of 0.028 cm2 of the equipment) and the dose will be 1 J per point. Irradiation will be performed on a cervical point, an apical point and a point precisely over the lesion, totaling a dose of 3 J. Treatment will be performed in three sessions with a 72-hour interval between sessions.
Study NCT06560502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnio Quad-Core - DFU
Description: Participants will receive weekly applications of Amnio Quad-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
Study NCT05678439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sesame extract
Description: At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of sesame extract (sesamin 37-56mg per capsule). The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
Study NCT05678439 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of placebo. The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
Study NCT05004792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DermLoop Learn
Description: DermLoop Learn is our AI-augmented digital educational platform with case training on a library of 18,000+ benign and malignant skin lesions, educational videos on the correlation between dermoscopy and histology, as well as written learning modules for the most common skin lesion diagnosis. The education platform will give the user feedback on the image-based case training in dermoscopic diagnostic accuracy and adjust the cases depending on the user's progression.
Study NCT06560502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care-VLU
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
Study NCT04883151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOFUS pilot program
Description: The SOFUS pilot program consists of six pre-loss sessions (Program 1) and a further six post-loss sessions (Program 2), which are delivered over a 3-month period. Each session ranges from 1-1.5 hours. Sessions 1 and 6 includes the whole family, sessions 2 and 3 focus on the parents, while sessions 4 and 5 target the children (with parents if the child is \<10 years old).~SOFUS consists of three primary components: i) strengthening COMMUNICATION between parents and children, ii) NORMALIZATION of grief processes (pre and post-lost), and iii) EMOTION REGULATION strategies targeting motivational awareness and regulatory skills in grief management (pre and post-lost).~Families in Program 1 may be offered Program 2 if the child dies before the entire program has been delivered.
Study NCT05060991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduction in antimetabolite immunosuppression
Description: Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination
Study NCT06447701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Single dose intravenous application
Study NCT06447701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9% 100ml
Description: Single dose intravenous application
Study NCT04178408 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06355375 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise in pregnancy
Description: aerobic exercise
Study NCT05383417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoClip
Description: Clip attached to mid portion of the endotracheal tube.
Study NCT04874818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [89Zr]Df-IAB22M2C PET/CT scan
Description: PET imaging procedure
Study NCT06560502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnio Tri-Core - VLU
Description: Participants will receive weekly applications of Amnio Tri-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
Study NCT06560502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmnioCore Pro
Description: Participants will receive weekly applications of AmnioCore Pro and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
Study NCT06560502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniocore Pro +
Description: Participants will receive weekly applications of Amniocore Pro + and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
Study NCT06293053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Injection solution~Route of administration: Subcutaneous
Study NCT05073120 — intervention group
Intervention type: OTHER
Intervention: Piqray Prescriber's/HCP guide for hyperglycemia
Description: oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA will be provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aims to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
Study NCT04993079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clotild®
Description: Use of Clotild® as neurovascular guidewire
Study NCT04758390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMARA (intervention group)
Description: The IMARA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
Study NCT04799262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 MG
Description: Oral tofacitinib at the dose of 5mg twice a day was given for 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if\<10 the daily GC dosage was decreased by 2.5mg; if>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
Study NCT04758390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion control group
Description: The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
Study NCT06299124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT-419B
Description: RGT-419B will be administered orally
Study NCT06419660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 300202
Description: BI 300202
Study NCT06419660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: esomeprazole
Study NCT06418061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI3005
Description: Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)
Study NCT04674969 — intervention group
Intervention type: DEVICE
Intervention: Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.
Description: Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
Study NCT05503459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicycle learning
Description: The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), bicycle learning (40 min), and cool-down (10 min). In the bicycle training activity, participants were asked to ride on a training bicycle with training wheels to gain better control of the bike in a gradual way. Participants then progressed from the training bicycle to a two-wheel bicycle. To keep participants on the learning curve, they were asked to ride through an obstacle course that was progressively more difficult to negotiate. The obstacles were designed by a focus group, which consisted of four physical education teachers from participating schools and one experienced cycling coach with more than five years of coaching experience.
Study NCT05503459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stationary cycling
Description: The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), stationary cycling (40 min), and cool-down (10 min). For stationary cycling activity, they were also asked every 10 mins during exercise to indicate their ratings of perceived exertion (target range: 3-5). Participants were positively reinforced verbally with compliments for their efforts in the training program and their daily improvements were visualized through graphs kept in the child's home.
Study NCT04559646 — intervention group
Intervention type: PROCEDURE
Intervention: Pacemaker implantation
Description: Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.
Study NCT04559646 — intervention group
Intervention type: DRUG
Intervention: Haemostatic solution Haemoblock application
Description: Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation.
Study NCT04559646 — intervention group
Intervention type: DRUG
Intervention: Saline solution application
Description: Saline solution will be used after pocket formation during pacemaker implantation.
Study NCT04559646 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound of pacemaker pocket
Description: Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.
Study NCT04559646 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.
Study NCT04559646 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Heart ultrasound examination for left ventricular ejection fraction measurement.
Study NCT05448378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol
Description: D-chiro-inositol 600 mg twice per day on an empty stomach for one month
Study NCT06421701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-NK cells
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) on day -5, -4, and -3. Doses of 2×10\^6/kg, 3×10\^6/kg, 4×10\^6/kg anti-CD19 CAR-NK cells will be infused in each group on Day 0, 7, and 14 using the 3 + 3 dose-escalation strategy.
Study NCT05684367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center-Based Walking Exercise
Description: Each exercise session will begin with a short warm-up followed by 30 min of walking. Participants will initially be instructed to walk at a moderate intensity, equivalent to a 5-6 on Borg category-ratio (CR) scale. Participants will be encouraged to, if possible, incorporate brief periods of vigorous walking (7-8 on CR10 scale) with a goal of achieving at least 10 min of vigorous walking per session.
Study NCT05684367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Walking Exercise
Description: Participants will be asked to walk for exercise in their community five days/week. Participants will be instructed to begin with 10-15 minutes of walking exercise/session in the first month of the intervention and to increase exercise duration by five minutes/session each week, facilitating reasonable but steady progress toward the goal of 30 minutes per session.
Study NCT05453110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deadlift Form Education
Description: The education will include information about the lumbar spine as it relates to a deadlift. The researchers will administer this education shortly prior to participants taking a strength test.
Study NCT05831124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose multivalent pneumococcal conjugate vaccine formulation A
Description: Biological